JOT is a Clinical stage CNS focused company. JOT's Platform product, JOTROL™, is applicable to several rare diseases, such as Ataxia's, LSD's and Mitochondrial Diseases. Non-dilutive financing, Phase I trial financing received from NIA, makes the approach to Alzheimer’s Disease very attractive and will be developed in parallel with the rare disease applications.